Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Stephen B. Shohet sold 7,866 shares of the business’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $18.87, for a total value of $148,431.42. Following the completion of the sale, the director now directly owns 31,982 shares of the company’s stock, valued at $603,500.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Amphastar Pharmaceuticals, Inc. (AMPH) traded down $0.48 during trading hours on Thursday, hitting $18.73. The stock had a trading volume of 164,067 shares, compared to its average volume of 289,773. The company has a market capitalization of $885.49, a price-to-earnings ratio of 128.40 and a beta of 1.69. Amphastar Pharmaceuticals, Inc. has a 52 week low of $12.05 and a 52 week high of $21.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.08 and a quick ratio of 1.86.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Wednesday, November 8th. The company reported $0.07 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.05. The company had revenue of $57.90 million during the quarter, compared to analyst estimates of $57.23 million. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. The business’s revenue was down 9.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.14 earnings per share. sell-side analysts forecast that Amphastar Pharmaceuticals, Inc. will post -0.03 EPS for the current fiscal year.
Several brokerages recently weighed in on AMPH. Piper Jaffray Companies reissued a “buy” rating and issued a $19.00 price objective on shares of Amphastar Pharmaceuticals in a report on Sunday, September 17th. Needham & Company LLC boosted their price objective on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a report on Friday, December 1st. Zacks Investment Research lowered Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Jefferies Group set a $19.00 price objective on Amphastar Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, October 29th. Finally, Raymond James Financial lowered Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 target price for the company. in a report on Thursday, November 9th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $20.86.
COPYRIGHT VIOLATION NOTICE: “Amphastar Pharmaceuticals, Inc. (AMPH) Director Sells $148,431.42 in Stock” was first reported by Week Herald and is owned by of Week Herald. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://weekherald.com/2017/12/14/amphastar-pharmaceuticals-inc-amph-director-sells-148431-42-in-stock.html.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.